Heart failure & cardiomyopathies
Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure
Main finding · MortalityResult — go to the resultEstimate 0.79 CI 0.66–0.96Authors' conclusion
This study suggests that in persons with HF and AD, treatment with ChEIs is associated with improved survival and a decreased risk of hospital care for HF, but results due to the type of ChEI vary.
Study context
- Population
- Patients with heart failure (HF) and Alzheimer's disease (AD)455 patients with and 455 without ChEI treatment
- Participants
- 455 vs 455
- Exposure
- Associations between ChEI-use and risk of mortality or hospitalization for HF, stroke, or myocardial infarction
- ChEI usen = 455
- Non-usen = 455
- Outcome
- Mortality
Methodological detailslinking registers for cognitive/dementia disorders, comorbidities, drug prescription, and death, in Sweden
- Linking registers for cognitive/dementia disorders, comorbidities, drug prescription, and death, in Sweden
Main finding
As reported in the abstract
Estimate
0.79
CI 0.66–0.96
Observational data: associations, not effects.
Further findings
| Outcome | Estimate |
|---|---|
| Hospitalization due to HFReduction by 47% | 0.53 (CI 0.38–0.75) |
Death, by type of ChEI
- Donepezil and galantamine but not rivastigmine were associated with a lower risk of death compared with non-users
Hospitalization due to HF, by type of ChEI
- Donepezil was associated with a lower risk of hospitalization due to HF compared with non-users
Hospitalization for bradycardia, AV block, or implantation of pacemaker
- No significant difference between ChEI use and non-use
Original publication
Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure. Eur Heart J Cardiovasc Pharmacother. Published 7 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →